Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Commentary
Video

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Paolo Ghia, MD, PhD, full professor, Medical Oncology, group leader, B-cell Neoplasia Unit, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial (NCT03336333) investigating zanubrutinib (Brukinsa) vs bendamustine (Bendeka) plus rituximab (Rituxan; BR) in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without 17p deletions.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD